Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
出版年份 2021 全文链接
标题
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-06-21
DOI
10.1186/s13045-021-01095-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors
- (2021) Kyriakos P. Papadopoulos et al. ONCOLOGIST
- Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
- (2019) Bixia Tang et al. Journal of Hematology & Oncology
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
- (2019) Marie Scully et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
- (2019) Yuankai Shi et al. Lancet Haematology
- Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors.
- (2019) Toshio Shimizu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.
- (2019) Jian-Ming Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- Structured literature review (SLR) and meta-analyses of the prevalence of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in gastric, colorectal, and esophageal cancers.
- (2019) Mayur Amonkar et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanobody approval gives domain antibodies a boost
- (2019) Chris Morrison NATURE REVIEWS DRUG DISCOVERY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- 1140PDPhase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA
- (2018) K P Papadopoulos et al. ANNALS OF ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
- (2017) Yelena Y. Janjigian et al. Cancer Discovery
- Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
- (2017) Fei Zhang et al. Cell Discovery
- Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers
- (2016) Chang Gon Kim et al. BRITISH JOURNAL OF CANCER
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
- (2009) M Koopman et al. BRITISH JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started